Drug Type Biosimilar, Monoclonal antibody |
Synonyms- |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date IR (01 Jan 2017), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colorectal Cancer | IR | 01 Jan 2017 |